Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1888-1892

  Pierard G E ^a   Pierard Franchimont C ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Growth fraction; Melanoma; Tumour thickness

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; THICKNESS; TUMOR VASCULARIZATION;

ADULT; CELL DIVISION; HUMANS; KI-67 ANTIGEN; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 0344301855     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00231-1     Document Type: Article

References (36)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Nad Cancer Inst 1990, 82, 4-6.
3. LJotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-337.
4. Fidler I, Ellis L. The implications of angiogenesis for the biology and therapy of cancer metastasis. Ceü 1994, 79, 185-188.
5. Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J Pathol 1996, 179, 232-237.
6. Srivastava A, Laidler P, Hughes LE, Woodcock J, Shedden EJ. Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. EUT J Cancer Clin Oncol 1986, 22, 1205-1209.
7. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of rumor vascularity in intermediatethickness (0.76-4.Omm thick) skin melanoma. Am J Pathol 1988, 133, 419-423.
8. Smolle J, Soyer HP, Hofmann-Wellenhof R, Smolle-Juettner FM, Kerl H. Vascular architecture of melanocytic skin tumors: a quantitative immunohistochemical study using automated image analysis. Pathol Res Pract 1989, 185, 740-745.
9. Carnochan P, Briggs J, Westbury G, Davies A. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer 1991, 64, 102-107.
10. Barnhill R, Frandrey K, Levy M, Mihm MJ, Hyman B. Angiogenesis and tumor progression of melanoma: quantification of vascularity in melanocytic nevi and cutaneous melanoma. Lab Invest 1992, 67, 331-337.
11. Barnhill RL, Levy MA. Regressing thin cutaneous malignant melanomas (less than or equal to 1.0mm) are associated with angiogenesis. Am J Pathol 1993, 143, 99-104.
12. Berger R, Albelda SM, Berd D, Ioffreda M, Whitaker D, Murphy GF. Expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J Cutan Pathol 1993, 20, 399-406.
13. Deijn M, Ruiter D. The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects. Melanoma Res 1993, 3, 5-14.
14. Vacca A, Ribatti D, Roncali L, Lospalluti M, Serio G, Carrel S, Dammacco F. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993, 72, 455-461.
15. Barnhill RL, Busam KJ, Berwick M, et al. Tumor vascularity is not a prognostic factor for cutaneous melanoma. Lancet 1994, 344, 1237-1238.
16. Glass LF, Guffey JM, Schroer KR, Reintgen D. Immunohistochemical assessment of tumor vascularity in recurrent Clark level II melanomas using antibody to type IV collagen. J Cutan Pathol 1994, 21, 542.
17. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as an independent prognostic indicator in thin (0.76mm) malignant melanomas. Am J Pathol 1994, 145, 510-514.
18. Busam KJ, Berwick M, Blessing K, et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 1995, 147, 1049-1056.
19. Kerbel RS, Kobayashi H, Graham CH, Lu C. Analysis and significance of the malignant 'eclipse' during the progression of primary cutaneous human melanomas. J Invest Dermatol Symp Proc 1996, 1, 183-187.
20. Rongioletti F, Miracco C, Gambini C, Pastorino A, Tosi P, Rebora A. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay. Am J Dermatopathol 1996, 18, 474-477.
21. Piérard GE, Piérard-Franchimont C, Henry C, Lapière M. The proliferative activity of cells of malignant melanomas. Am J Dermatopathol 1984, 6 (Suppl. 1), 317-324.
22. Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stolz W, Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. AmJPathol 1989, 134, 1063-1068.
23. Ostmeier H, Suter L. The Ki-67 antigen in primary human melanomas-its relationship to mitotic rate and tumor thickness and its stability. Arch Dermatol Res 1989, 281, 173-177.
24. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. Am J Dermatopathol 1989, 11, 301-307.
25. Soyer HP. Ki-67 immunostaining in melanocytic skin tumors. Correlation with histologie parameters. J Cutan Pathol 1991, 18, 264-272.
26. Piérard-Franchimont C, Piérard GE. Karyometry of primary and metastatic malignant melanoma. A correlation with cell proliferation. Am y Dermatopathol 1994, 16, 247-252.
27. Fogt F, Vortmeyer AO, Tahan SR. Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. A m J Dermatopathol 1995, 17, 12-27.
28. Piérard-Franchimont C, Arrese JE, Nikkels AF, AI Saleh W, Delvenne P, Pierard GE. Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch 1996, 429, 43-48.
29. Ordonez N, Batsakis J. Comparison of Ulex europaeus I lectin and factor Vlll-related antigen in vascular lesions. Arch Pathol Lab Med 1984, 108, 129-132.
30. Little D, Said J, Siegel R, Fealy M, Fishbein M. Endothelial cell markers in vascular neoplasms: an immunohistochemical study comparing factor Vlll-related antigen, blood group specific antigens, 6-keto-PGFl-a, and Ulex europaeus 1 lectin. J Pathol 1986, 149, 89-95.
31. Morphopoulos G, Pearson M, Ryden WJD, Howell A, Harris M. Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 1996, 180, 44-49.
32. Fidler IJ . Critical determinants of melanoma metastasis. J Invest Dermatol Symp Proc 1996, 1, 203-208.
33. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995, 3, 75-84.
34. Stenzinger W, Bruggen J, Macher E, Sorg C. Tumour angiogenic activity (TAA) production in vitro and growth in the nude mouse by human malignant melanoma. Eur J Cancer Clin Oncol 1986, 22, 1205-1209.
35. Folkman J. What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Cancer Clin Oncol 1987, 23, 361-363.
36. Walker RA. Angiogenesis and breast cancer prognosis-a continuing issue. J Pathol 1996, 180, 6-7.